Completion of sale of VelosBio

VelosBio to be acquired by Merck for $2.75 billion

VelosBio Announces First Patient Dosed in Phase 2 Trial of VLS-101 in Solid Tumors

VelosBio Announces FDA Fast Track and Orphan Drug Designations for VLS-101 in Patients with Mantle Cell Lymphoma

VelosBio Appoints Dr. Enoch Kariuki as Chief Financial Officer

VelosBio Raises $137 Million in Series B Financing to Advance Development of ROR1-Directed Therapeutics in Oncology

Arix 2019 Capital Markets Day

Arix Bioscience Co-leads $58 million Series A investment round for VelosBio